NGL Fine-Chem Q1FY27 Cons. Revenue ₹14,659 Lakh, Profit ₹1,840 Lakh
NGL Fine-Chem reported Q1FY27 consolidated revenue of ₹14,659 lakh and profit after tax of ₹1,840 lakh. Standalone revenue was ₹13,916 lakh with profit after tax of ₹1,840 lakh. The results were approved by the Board on August 12, 2026.
The announcement details the financial results for the quarter, which are material information for investors and directly impact the company's valuation and stock performance.
The company reported significant year-on-year growth in both revenue and profit for the quarter ended June 30, 2026, indicating strong financial performance.
NGL Fine-Chem Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated financial results during their meeting held on August 12, 2026.
For the quarter ended June 30, 2026, the consolidated total revenue stood at ₹14,659.09 lakh, a significant increase from ₹11,053.89 lakh in the same quarter of the previous year. Profit after tax from continuing operations (consolidated) was ₹1,839.72 lakh, compared to ₹924.06 lakh in the corresponding quarter of FY26. The consolidated earnings per share (EPS) for basic and diluted were ₹29.78.
On a standalone basis, the company reported total revenue of ₹13,916.28 lakh for the quarter ended June 30, 2026, up from ₹10,418.54 lakh in the prior year's quarter. Standalone profit after tax from continuing operations was ₹1,839.72 lakh, an increase from ₹924.06 lakh in the same period last year. The standalone EPS (basic and diluted) was ₹29.78.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors. The figures were subjected to a limited review by the statutory auditors. The company operates in a single business segment, pharmaceuticals, in accordance with IND-AS 108.
What to do with a filing like this
NGL Fine-Chem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by NGL Fine-Chem Limited. Read the original for the full detail.